IBI101 is an OX40 agonist intended for the treatment of a variety of solid tumor diseases. Data from preclinical studies confirm that IBI101 has a well-defined mechanism of action, which significantly enhances the activation of effector T cells and mediates the clearance of tregs, thereby acting to inhibit the growth of tumor cells. Here, TNFRSF4 is linked to neoplasm.